ACM
PBYI icon

Athyrium Capital Management’s Puma Biotechnology PBYI Stock Holding History

Athyrium Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.2M Hold
1,256,411
– – 36.88% 2
2024
Q2 		$4.1M Hold
1,256,411
– – 12.21% 3
2024
Q1 		$6.66M Sell
1,256,411
-535,703
-30% -$2.88M 9.15% 3
2023
Q4 		$7.76M Hold
1,792,114
– – 11.27% 3
2023
Q3 		$4.71M Hold
1,792,114
– – 4.15% 5
2023
Q2 		$6.33M Hold
1,792,114
– – 4.1% 7
2023
Q1 		$5.54M Hold
1,792,114
– – 1.98% 7
2022
Q4 		$7.58M Hold
1,792,114
– – 3.19% 9
2022
Q3 		$4.25M Hold
1,792,114
– – 1.59% 10
2022
Q2 		$5.11M Hold
1,792,114
– – 2.15% 10
2022
Q1 		$5.16M Buy
+1,792,114
New +$4.64M 1.83% 9

Other funds holding PBYI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Athyrium Capital Management's PBYI Position: Q3 2024 in Review

Athyrium Capital Management held its Puma Biotechnology (PBYI) position steady in Q3 2024 at 1,256,411 shares worth $3.2M. The position accounts for 36.88% of the portfolio, ranked #2.

Athyrium Capital Management first reported a position in PBYI in Q1 2022 and has held it in 11 quarters since. The position peaked at $7.76M in Q4 2023. 100 funds tracked by Wall St. Rank hold PBYI as of Q3 2024.

  • Athyrium Capital Management held 1,256,411 shares of Puma Biotechnology worth $3.2M as of Q3 2024.
  • Athyrium Capital Management left its Puma Biotechnology share count unchanged in Q3 2024.
  • Puma Biotechnology made up 36.88% of Athyrium Capital Management's portfolio in Q3 2024, its #2 holding.
  • Athyrium Capital Management first reported a position in Puma Biotechnology in Q1 2022 and has held it in 11 quarters since.
  • Athyrium Capital Management's Puma Biotechnology position peaked at $7.76M in Q4 2023.
  • 100 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2024.

Based on Athyrium Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.